DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the IPCA LABORATORIES LTD (IPCALAB) share price today?

IPCA LABORATORIES LTD (IPCALAB) is trading at ₹1,900.6 on the NSE, up 0.55% on the day. Source: DocStoX.

What is the PE ratio of IPCA LABORATORIES LTD?

IPCA LABORATORIES LTD has a price-to-earnings (PE) ratio of 42.3 in the Healthcare sector.

What is the market capitalisation of IPCA LABORATORIES LTD?

IPCA LABORATORIES LTD has a market capitalisation of approximately ₹48,239 crore.

IPCA LABORATORIES LTD

IPCALAB·NSE·Healthcare

₹1,900.60▲ +10.40 (+0.55%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 500NIFTY MIDCAP 150NIFTY PHARMA

Day₹1846.80

₹1944.90

52W₹1252

₹194594%

Open

₹1888.00

High

₹1944.90

Low

₹1846.80

Prev Close

₹1890.20

Volume

1.57L

VWAP

₹1887.06

Snapshot

Key fundamentals

Market Cap

₹48,239 Cr

P/E Ratio

42.25Expensive

P/B Ratio

5.41

EPS

₹44.98

Book Value

₹318.00

ROE

16.00%Strong

ROCE

17.00%Decent

Dividend Yield

0.23%

Debt / Equity

0.10Low

Face Value

₹1.00

52W High

₹1944.90

52W Low

₹1251.60

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹425

▼ 77.6%downside

Trading at ₹1,901 — 78% above our estimate

BearFair valueBull

₹362₹425₹567

/100

Business quality — Solid

Growth 82Profitability 56Efficiency 23Valuation 57

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Revenue compounding 16% over 3 years
Profit growing 35% a year

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

16% ROE fading to 12% over ~10 yrs, on ₹318 book

₹386

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹567

Analyst target

No analyst coverage

—

Blended fair value₹425

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 16% over 3 years
Profit growing 35% a year

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

42.3Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

16.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.10Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹48,239 Cr

P/B

5.41

EPS

₹44.98

Div Yield

0.23%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 42.3×

Growth

Strong

+16% rev CAGR

Profitability

Healthy

16.0% ROE

Financial health

Rock solid

D/E 0.10

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.5%

Turnover₹2967.69L Cr

Trades14,775

VWAP₹1887.06

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.8%

+12.3%

10Y

+12.9%

Profit

+35.2%

+0.7%

10Y

+29.0%

EPS

+34.3%

+0.0%

10Y

+28.4%

Profile

Pros

Company has reduced debt.

Watch-outs

Cons

Stock is trading at 5.63 times its book value
Company has a low return on equity of 13.1% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

45%

Promoter

Promoters

44.7%0.00

Public

7.2%-0.02

FII / FPI

10.7%+0.09

DII

37.0%-0.09

Quarterly trend

Ownership over time

Q1 FY27

Promoter44.72%

FII10.72%

DII37.04%

Public7.19%

Others0.33%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)